BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones JL, Nguyen GC, Benchimol EI, Bernstein CN, Bitton A, Kaplan GG, Murthy SK, Lee K, Cooke-Lauder J, Otley AR. The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life. J Can Assoc Gastroenterol 2019;2:S42-8. [PMID: 31294384 DOI: 10.1093/jcag/gwy048] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Kutschera M, Waldhör T, Gröchenig HP, Haas T, Wenzl H, Steiner P, Koch R, Feichtenschlager T, Eckhardt G, Mayer A, Kirchgatterer A, Ludwiczek O, Platzer R, Papay P, Gartner J, Fuchssteiner H, Peters PG, Reicht G, Moser G, Dejaco C, Vogelsang H, Primas C, Novacek G, Miehsler W; Austrian IBD Study Group. Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease. United European Gastroenterol J 2021;9:72-81. [PMID: 32723070 DOI: 10.1177/2050640620946874] [Reference Citation Analysis]
2 Paulides E, Boukema I, van der Woude CJ, de Boer NKH. The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review. Inflamm Bowel Dis 2021;27:711-24. [PMID: 32737977 DOI: 10.1093/ibd/izaa144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
3 Nazarian A, Bishay K, Gholami R, Scaffidi MA, Khan R, Cohen-Lyons D, Griller N, Satchwell JB, Baker JP, Grover SC, Irvine EJ. Factors Associated with Poor Quality of Life in a Canadian Cohort of Patients with Inflammatory Bowel Disease: A Cross-sectional Study. J Can Assoc Gastroenterol 2021;4:91-6. [PMID: 33855267 DOI: 10.1093/jcag/gwaa014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Reference Citation Analysis]
5 Kuźnicki P, Neubauer K. Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse. J Clin Med 2021;10:4623. [PMID: 34640641 DOI: 10.3390/jcm10194623] [Reference Citation Analysis]
6 Bollegala N, Barwick M, Fu N, Griffiths AM, Keefer L, Kohut SA, Kroeker KI, Lawrence S, Lee K, Mack DR, Walters TD, de Guzman J, Tersigni C, Miatello A, Benchimol EI. Multimodal intervention to improve the transition of patients with inflammatory bowel disease from pediatric to adult care: protocol for a randomized controlled trial. BMC Gastroenterol 2022;22:251. [PMID: 35585484 DOI: 10.1186/s12876-022-02307-9] [Reference Citation Analysis]
7 Chen J, Mittendorfer-Rutz E, Berg L, Norredam M, Sijbrandij M, Klimek P. Associations between Multimorbidity Patterns and Subsequent Labor Market Marginalization among Refugees and Swedish-Born Young Adults-A Nationwide Registered-Based Cohort Study. J Pers Med 2021;11:1305. [PMID: 34945776 DOI: 10.3390/jpm11121305] [Reference Citation Analysis]
8 Day AS, Yao CK, Costello SP, Andrews JM, Bryant RV. Food-related quality of life in adults with inflammatory bowel disease is associated with restrictive eating behaviour, disease activity and surgery: A prospective multicentre observational study. J Hum Nutr Diet 2021. [PMID: 34008222 DOI: 10.1111/jhn.12920] [Reference Citation Analysis]
9 Castellano F, Alessio G, Palmisano C. Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists. Minerva Gastroenterol (Torino) 2021;67:91-100. [PMID: 32677418 DOI: 10.23736/S2724-5985.20.02727-0] [Reference Citation Analysis]
10 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Reference Citation Analysis]
11 Griffiths OR, Landon J, Coxon RE, Morris K, James P, Adams R. Inflammatory bowel disease and targeted oral anti-TNFα therapy. Adv Protein Chem Struct Biol 2020;119:157-98. [PMID: 31997768 DOI: 10.1016/bs.apcsb.2019.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wils P, Caron B, D’amico F, Danese S, Peyrin-biroulet L. Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge. JCM 2022;11:4269. [DOI: 10.3390/jcm11154269] [Reference Citation Analysis]
13 Jonaitis L, Marković S, Farkas K, Gheorghe L, Krznarić Ž, Salupere R, Mokricka V, Spassova Z, Gatev D, Grosu I, Lijović A, Mitrović O, Saje M, Schafer E, Uršič V, Roblek T, Drobne D. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert's and patient's perspective. BMC Proc 2021;15:25. [PMID: 34879868 DOI: 10.1186/s12919-021-00230-7] [Reference Citation Analysis]
14 Vecchiarelli HA, Morena M, Keenan CM, Chiang V, Tan K, Qiao M, Leitl K, Santori A, Pittman QJ, Sharkey KA, Hill MN. Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase. Neuropsychopharmacology 2021;46:992-1003. [PMID: 33452437 DOI: 10.1038/s41386-020-00939-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Paulides E, Pasma A, Erler NS, van Eijk RLA, de Vries AC, van der Woude CJ. Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34181168 DOI: 10.1007/s10620-021-07118-8] [Reference Citation Analysis]
16 Windsor JW, Kaplan GG. Evolving Epidemiology of IBD. Curr Gastroenterol Rep. 2019;21:40. [PMID: 31338613 DOI: 10.1007/s11894-019-0705-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 16.3] [Reference Citation Analysis]
17 Abu Sneineh A, Haj Ali S, Al-Masri A, Diab A, Aldweik F, Darweesh M, Qaisi M, Alshakhatreh O, Tamimi T, Rayyan Y, Banimustafa R, Sablaban I. Prevalence of anxiety and depressive symptoms in ulcerative colitis patients in Jordan and its relationship to patient-reported disease activity. Sci Rep 2022;12:7682. [PMID: 35538204 DOI: 10.1038/s41598-022-11911-4] [Reference Citation Analysis]
18 Irving P, Barrett K, Nijher M, de Lusignan S. Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study. Evid Based Ment Health 2021:ebmental-2020-300223. [PMID: 33785498 DOI: 10.1136/ebmental-2020-300223] [Reference Citation Analysis]
19 Li Y, Jiang Y, Zhang L, Qian W, Hou X, Lin R. Exogenous l-fucose protects the intestinal mucosal barrier depending on upregulation of FUT2-mediated fucosylation of intestinal epithelial cells. FASEB J 2021;35:e21699. [PMID: 34151459 DOI: 10.1096/fj.202002446RRRR] [Reference Citation Analysis]
20 Cioffi I, Imperatore N, Di Vincenzo O, Santarpia L, Rispo A, Marra M, Testa A, Contaldo F, Castiglione F, Pasanisi F. Association between Health-Related Quality of Life and Nutritional Status in Adult Patients with Crohn's Disease. Nutrients 2020;12:E746. [PMID: 32168964 DOI: 10.3390/nu12030746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Silva LC, Seixas RBPM, de Carvalho E. Quality of Life in Children and Adolescents with Inflammatory Bowel Disease: Impact and Predictive Factors. Pediatr Gastroenterol Hepatol Nutr 2020;23:286-96. [PMID: 32483550 DOI: 10.5223/pghn.2020.23.3.286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Naftali T, Richter V, Mari A, Khoury T, Shirin H, Broide E. The inflammatory bowel disease disk application: A platform to assess patients' priorities and expectations from treatment. J Dig Dis 2021;22:582-9. [PMID: 34431218 DOI: 10.1111/1751-2980.13045] [Reference Citation Analysis]
23 Mathias H, Heisler C, Morrison J, Currie B, Phalen-Kelly K, Jones J. Examining the Association Between Referral Quality, Wait Time and Patient Outcomes for Patients Referred to an IBD Specialty Program. J Can Assoc Gastroenterol 2020;3:154-61. [PMID: 32671324 DOI: 10.1093/jcag/gwz002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
25 Connor SJ, Sechi A, Andrade M, Deuring JJ, Witcombe D. Ulcerative Colitis Narrative findings: Australian survey data comparing patient and physician disease management views. JGH Open 2021;5:1033-40. [PMID: 34584972 DOI: 10.1002/jgh3.12627] [Reference Citation Analysis]